Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

The clinical hold was placed on three studies investigating azenosertib in June after two patients died due to presumed ...

Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...

While the FDA will take into consideration the committee’s vote, the vote is not binding upon the agency. The FDA will make the final decision and has assigned a Prescription Drug User Fee Act (PDUFA) ...

Data demonstrate broad activity of CBX-12 across six tumor types with a strong response rate in TOP1-naïve patients with ovarian (40%; N=10) and ...

According to the company, topline results will be presented at the 2024 American Academy of Ophthalmology Annual Meeting, ...

Experimental in vivo testing in-house and by its existing licensees has shown that ADCs built using Synaffix technology offer an improved therapeutic index over ADCs prepared from antibody–drug ...

To address these limitations, XWPharma developed XW10508 as an esketamine-based therapy with an optimized therapeutic index. XW10508 is a glutamatergic NMDA antagonist and AMPA activator designed ...

Seven independent members of the company’s board resigned Tuesday, concluding that despite co-founder and CEO Anne Wojcicki’s ...

- To establish if potential adverse effects and toxic effects of Lithium are discussed with patients - To establish if any side effects, or lack of, are recorded South Eastern HSC Trust is an ...

( MENAFN - Jordan Times) AMMAN - The Jordan Chamber of industry said that the industry index, recorded a growth of 1 per cent ...